Intuitive Surgical, Inc.'s Stock Analysis

Intuitive Surgical Announces Leadership Changes in Key Roles

Effective July 1, 2026, Taylor Patton will take over as Chief Commercial and Marketing Officer of Intuitive Surgical, succeeding Henry L. Charlton, who will become Senior Vice President of Global Business Operations. Patton has nearly two decades of experience at Intuitive and has held various leadership positions, including overseeing the launch of the Ion platform, which involved extensive commercial and clinical initiatives across multiple regions.

The leadership transition aims to support Intuitive's ongoing global growth and enhance customer support in minimally invasive care. Charlton's new role will focus on generating value for patients and healthcare systems, while Patton will lead efforts to scale commercial operations and ensure consistent service delivery. The company emphasizes its commitment to improving patient outcomes through advanced technologies and comprehensive support for healthcare providers.

May 28, 2026 16:35:49

Intuitive Surgical Increases Share Repurchase Program to $5 Billion

Intuitive Surgical's stockholders approved several proposals at the annual meeting held on April 30, 2026, including the amendment and restatement of the 2010 Incentive Award Plan, which increased the number of shares available for issuance from 120,350,000 to 125,350,000 and extended the plan's term to January 29, 2036. Additionally, stockholders elected ten board members, approved the advisory compensation for Named Executive Officers, and ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

The Board also increased the authorized amount for the common stock repurchase program to $5.0 billion. This program allows for repurchases to be made based on market conditions and does not obligate the company to acquire a specific amount of stock. The funding for the repurchase program is expected to come from cash, cash equivalents, and investments, and the timing and amount of repurchases may vary.

May 04, 2026 16:05:32

Intuitive Surgical Reports Q1 2026 Financial Results and Growth

Intuitive Surgical announced its financial results for the first quarter of 2026, reporting a revenue of $2.77 billion, a 23% increase from $2.25 billion in the same period last year. The growth was attributed to a 17% increase in worldwide procedures, with da Vinci procedures growing by 16% and Ion procedures by 39%. The company placed 431 da Vinci surgical systems in Q1 2026, up from 367 in Q1 2025, and increased its installed base of da Vinci systems to 11,395, marking a 12% year-over-year growth.

The company's net income attributable to Intuitive Surgical was $822 million, or $2.28 per diluted share, compared to $698 million, or $1.92 per diluted share in the prior year. Non-GAAP net income for the quarter was $901 million, or $2.50 per diluted share, up from $662 million, or $1.81 per diluted share in Q1 2025. The company also repurchased 2.3 million shares of its common stock for $1.1 billion during the quarter, while ending the period with $7.98 billion in cash and investments, which decreased by $1.05 billion mainly due to stock repurchases and a business acquisition.

Apr 21, 2026 16:09:36

Intuitive Surgical Completes Acquisition of European Distribution Business

Intuitive Surgical has completed its acquisition of the da Vinci and Ion distribution business from ab medica, Abex, and Excelencia Robótica, effective March 1, 2026. This acquisition allows Intuitive to expand its direct operations in several European countries, including Italy, Spain, Portugal, Malta, and San Marino, enhancing its ability to support customers and increase access to minimally invasive care in these regions.

The integration of approximately 250 employees from the acquired businesses into Intuitive's European commercial and marketing organization is expected to strengthen its presence and operational capabilities in Southern Europe. As of December 31, 2025, there were over 470 da Vinci surgical systems installed across Italy, Spain, and Portugal, with the Ion endoluminal system recently launched in these markets.

Mar 02, 2026 17:13:42

Intuitive Surgical Reports 19% Revenue Growth in Q4 2025

Intuitive Surgical announced its financial results for the fourth quarter of 2025, reporting revenue of $2.87 billion, a 19% increase from $2.41 billion in the same quarter of 2024. The growth was driven by an 18% increase in worldwide procedures, with da Vinci procedures growing 17% and Ion procedures growing 44%. The company placed 532 da Vinci surgical systems during the quarter, up from 493 systems in the prior year, contributing to an installed base of 11,106 da Vinci systems, a 12% increase year-over-year.

The company's GAAP net income for the fourth quarter was $795 million, or $2.21 per diluted share, compared to $686 million, or $1.88 per diluted share, in the fourth quarter of 2024. Non-GAAP net income was reported at $914 million, or $2.53 per diluted share, up from $805 million, or $2.21 per diluted share, a year earlier. Intuitive Surgical ended the quarter with $9.03 billion in cash and investments, reflecting a $0.60 billion increase driven by operational cash flow, despite expenditures on stock repurchases and capital investments.

Jan 22, 2026 16:05:12

Intuitive Surgical Reports Preliminary 2025 Financial Results

Intuitive Surgical announced preliminary financial results for the fourth quarter and full year 2025, highlighting a 19% increase in revenue for Q4, reaching approximately $2.87 billion, compared to $2.41 billion in Q4 2024. For the full year, revenue rose 21% to approximately $10.06 billion, up from $8.35 billion in 2024. The growth was attributed to an increase in procedure volume and higher placements of da Vinci surgical systems, which saw an 18% rise in total procedures performed, with significant contributions from both U.S. and international markets.

During Q4 2025, the company placed 532 da Vinci surgical systems and noted a 4% increase in average system utilization. The report indicated that 2025 saw a total of 1,721 da Vinci system placements, up from 1,526 in 2024. Additionally, instruments and accessories revenue for Q4 2025 rose 17% to approximately $1.66 billion. The company expects continued growth in procedure volume, forecasting a 13% to 15% increase in worldwide da Vinci procedures for 2026.

Jan 14, 2026 08:58:49

Leadership Transition in Digital and AI Strategy at Intuitive Surgical

Effective January 1, 2026, Brian E. Miller, Ph.D., will change his position from Chief Digital Officer to Head of Digital and AI Strategy at Intuitive Surgical. Following this transition, Dr. Miller will no longer report directly to the Chief Executive Officer.

Dec 18, 2025 17:02:23

Intuitive Surgical Reports 23% Revenue Growth in Q3 2025

Intuitive Surgical announced its financial results for the third quarter of 2025, reporting a revenue of $2.51 billion, which is a 23% increase from $2.04 billion in the same quarter of 2024. The growth was driven by a 20% rise in worldwide procedures, with da Vinci procedures growing by 19% and Ion procedures by 52%. The company also placed 427 da Vinci surgical systems during the quarter, up from 379 in the prior year, contributing to an increase in the installed base to 10,763 systems, a 13% rise year-over-year.

The company reported a GAAP net income of $704 million, or $1.95 per diluted share, compared to $565 million, or $1.56 per diluted share, in Q3 2024. Non-GAAP net income for the quarter was $867 million, or $2.40 per diluted share, reflecting growth from $669 million, or $1.84 per diluted share, in the previous year. Intuitive Surgical ended the quarter with $8.43 billion in cash, cash equivalents, and investments, a decrease attributed to share repurchases and capital expenditures.

Oct 21, 2025 16:03:44

Intuitive Announces CEO Transition Effective July 2025

Intuitive Surgical has announced that Dave Rosa, currently the President, will be promoted to Chief Executive Officer effective July 1, 2025. This transition will see current CEO Gary Guthart take on the role of executive chair of the board, while Craig Barratt, the current Board Chair, will become the lead independent director. Guthart will assist Rosa during the transition and continue to advise the company in a senior capacity.

Dave Rosa has been with Intuitive for nearly 30 years, holding various leadership roles that include engineering, product development, and strategic growth. His experience includes founding key groups within the company and overseeing the development of significant products such as the da Vinci SP robotic-assisted surgical system. The company is marking its 30th year in robotic-assisted technology, emphasizing its commitment to improving patient outcomes and expanding access to minimally invasive care.

May 15, 2025 09:05:20

Intuitive Reports 19% Revenue Growth in Q1 2025 Earnings

Intuitive Surgical announced its financial results for the first quarter of 2025, reporting a revenue of $2.25 billion, which represents a 19% increase compared to $1.89 billion in the same quarter of 2024. The growth was attributed to a rise in da Vinci procedures, higher placements of da Vinci surgical systems, and an expanded installed base, which reached 10,189 systems, up 15% from the previous year. The company placed 367 da Vinci systems during the quarter, significantly up from 313 in Q1 2024, with a notable increase in the placement of da Vinci 5 systems from 8 to 147 units year-over-year.

GAAP net income for the first quarter was $698 million, or $1.92 per diluted share, compared to $545 million, or $1.51 per diluted share, in the first quarter of 2024. Non-GAAP net income was reported at $662 million, or $1.81 per diluted share, also showing an increase from $541 million, or $1.50 per diluted share, in the prior year. The company ended the quarter with $9.10 billion in cash and investments, reflecting a $269 million increase, primarily due to cash generated from operations.

Apr 22, 2025 16:03:30